| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV Antibodies | 15 | 2019 | 776 | 3.90 | Why? |
| HIV-1 | 17 | 2020 | 3365 | 2.53 | Why? |
| Antibodies, Neutralizing | 37 | 2021 | 25288 | 1.75 | Why? |
| B-Lymphocytes | 10 | 2021 | 4418 | 1.14 | Why? |
| Antibodies, Monoclonal | 16 | 2021 | 8041 | 0.91 | Why? |
| HIV Infections | 13 | 2019 | 11620 | 0.90 | Why? |
| Antibody Affinity | 3 | 2021 | 1078 | 0.80 | Why? |
| Viremia | 5 | 2018 | 1020 | 0.76 | Why? |
| Precursor Cells, B-Lymphoid | 1 | 2018 | 12 | 0.76 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 6 | 2018 | 386 | 0.70 | Why? |
| HIV Antigens | 1 | 2018 | 102 | 0.69 | Why? |
| Antibodies, Viral | 18 | 2021 | 51949 | 0.69 | Why? |
| Virus Latency | 2 | 2018 | 251 | 0.68 | Why? |
| HLA-B27 Antigen | 1 | 2017 | 48 | 0.66 | Why? |
| HLA-B Antigens | 1 | 2017 | 166 | 0.60 | Why? |
| AIDS Vaccines | 2 | 2017 | 452 | 0.58 | Why? |
| Immunity, Humoral | 2 | 2021 | 4849 | 0.58 | Why? |
| Calcium Signaling | 1 | 2014 | 133 | 0.52 | Why? |
| Autoantibodies | 3 | 2021 | 2094 | 0.51 | Why? |
| HIV Envelope Protein gp120 | 4 | 2018 | 267 | 0.48 | Why? |
| Recombination, Genetic | 2 | 2020 | 1265 | 0.47 | Why? |
| Neutralization Tests | 13 | 2021 | 6698 | 0.47 | Why? |
| Immunoglobulin A | 2 | 2021 | 3567 | 0.47 | Why? |
| Histocompatibility Antigens Class II | 1 | 2014 | 383 | 0.45 | Why? |
| Germinal Center | 1 | 2014 | 332 | 0.45 | Why? |
| Leukocytes, Mononuclear | 2 | 2018 | 2115 | 0.44 | Why? |
| CRISPR-Cas Systems | 2 | 2021 | 1397 | 0.43 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2014 | 497 | 0.42 | Why? |
| Mutation | 12 | 2021 | 12376 | 0.40 | Why? |
| Epitopes | 8 | 2021 | 4113 | 0.40 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.39 | Why? |
| HIV Envelope Protein gp160 | 2 | 2018 | 33 | 0.37 | Why? |
| Somatic Hypermutation, Immunoglobulin | 3 | 2021 | 283 | 0.37 | Why? |
| Mice | 15 | 2021 | 21357 | 0.36 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.35 | Why? |
| Immunologic Memory | 4 | 2021 | 3362 | 0.35 | Why? |
| Spike Glycoprotein, Coronavirus | 15 | 2021 | 37182 | 0.35 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.34 | Why? |
| Antibodies, Bispecific | 2 | 2021 | 207 | 0.34 | Why? |
| CD4 Antigens | 2 | 2018 | 306 | 0.32 | Why? |
| Host-Pathogen Interactions | 3 | 2021 | 11041 | 0.31 | Why? |
| Simian Acquired Immunodeficiency Syndrome | 2 | 2018 | 154 | 0.31 | Why? |
| CD4-Positive T-Lymphocytes | 3 | 2018 | 4545 | 0.31 | Why? |
| HEK293 Cells | 8 | 2020 | 8394 | 0.30 | Why? |
| Immunization, Passive | 4 | 2020 | 10067 | 0.29 | Why? |
| Simian Immunodeficiency Virus | 2 | 2018 | 251 | 0.29 | Why? |
| Viral Load | 6 | 2021 | 15850 | 0.28 | Why? |
| Immunotherapy | 1 | 2018 | 2421 | 0.28 | Why? |
| Animals | 24 | 2021 | 78931 | 0.27 | Why? |
| Clinical Trials as Topic | 2 | 2020 | 7330 | 0.26 | Why? |
| Zika Virus Infection | 1 | 2017 | 1920 | 0.25 | Why? |
| Interferon Type I | 3 | 2021 | 2789 | 0.25 | Why? |
| Viral Vaccines | 2 | 2020 | 7560 | 0.24 | Why? |
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 93 | 0.22 | Why? |
| Adoptive Transfer | 2 | 2019 | 250 | 0.21 | Why? |
| Antibodies, Monoclonal, Murine-Derived | 1 | 2021 | 94 | 0.21 | Why? |
| Cryoelectron Microscopy | 4 | 2021 | 2372 | 0.21 | Why? |
| Antigens, Viral | 4 | 2021 | 6298 | 0.21 | Why? |
| Immunoglobulin G | 9 | 2021 | 21571 | 0.21 | Why? |
| Mice, Transgenic | 2 | 2018 | 2739 | 0.20 | Why? |
| Models, Molecular | 7 | 2021 | 7616 | 0.20 | Why? |
| Camelids, New World | 1 | 2021 | 276 | 0.20 | Why? |
| Immunoglobulin Fab Fragments | 2 | 2020 | 556 | 0.20 | Why? |
| Protein Multimerization | 3 | 2020 | 1336 | 0.20 | Why? |
| Gene Editing | 2 | 2021 | 330 | 0.19 | Why? |
| Historically Controlled Study | 1 | 2018 | 71 | 0.19 | Why? |
| Proviruses | 1 | 2018 | 82 | 0.18 | Why? |
| INDEL Mutation | 1 | 2019 | 128 | 0.18 | Why? |
| Young Adult | 11 | 2021 | 93724 | 0.18 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.18 | Why? |
| Loss of Function Mutation | 1 | 2020 | 244 | 0.18 | Why? |
| Fluorescent Antibody Technique | 1 | 2021 | 835 | 0.17 | Why? |
| Humans | 46 | 2021 | 930598 | 0.17 | Why? |
| HIV Envelope Protein gp41 | 1 | 2018 | 153 | 0.17 | Why? |
| Cell Division | 1 | 2017 | 136 | 0.17 | Why? |
| Binding Sites, Antibody | 1 | 2018 | 466 | 0.17 | Why? |
| Mutagenesis, Insertional | 1 | 2017 | 92 | 0.17 | Why? |
| DNA Damage | 2 | 2017 | 285 | 0.16 | Why? |
| Virus Integration | 1 | 2017 | 96 | 0.16 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.16 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 7868 | 0.16 | Why? |
| Adult | 15 | 2021 | 244371 | 0.16 | Why? |
| Homeodomain Proteins | 1 | 2017 | 93 | 0.16 | Why? |
| Aged | 14 | 2021 | 215776 | 0.16 | Why? |
| Receptors, Fc | 1 | 2017 | 153 | 0.16 | Why? |
| HIV Seropositivity | 1 | 2018 | 320 | 0.15 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.15 | Why? |
| Epitopes, B-Lymphocyte | 2 | 2021 | 1267 | 0.15 | Why? |
| Periodicals as Topic | 2 | 2020 | 1492 | 0.15 | Why? |
| Protein Engineering | 1 | 2019 | 536 | 0.15 | Why? |
| Crystallography, X-Ray | 3 | 2018 | 2689 | 0.15 | Why? |
| Antibody Specificity | 1 | 2020 | 1328 | 0.15 | Why? |
| Vaccination | 2 | 2020 | 19050 | 0.14 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.14 | Why? |
| Inhibitory Concentration 50 | 1 | 2018 | 907 | 0.14 | Why? |
| Genetic Engineering | 1 | 2016 | 325 | 0.14 | Why? |
| Intestines | 1 | 2021 | 817 | 0.14 | Why? |
| Female | 21 | 2021 | 380317 | 0.14 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.13 | Why? |
| Single-Domain Antibodies | 1 | 2021 | 744 | 0.13 | Why? |
| New York | 2 | 2021 | 2488 | 0.13 | Why? |
| DNA-Binding Proteins | 1 | 2017 | 469 | 0.13 | Why? |
| Virus Activation | 1 | 2018 | 480 | 0.13 | Why? |
| Molecular Imaging | 1 | 2014 | 110 | 0.13 | Why? |
| T-Lymphocyte Subsets | 1 | 2021 | 1387 | 0.13 | Why? |
| Male | 17 | 2021 | 367725 | 0.13 | Why? |
| Green Fluorescent Proteins | 1 | 2014 | 450 | 0.13 | Why? |
| United States Food and Drug Administration | 1 | 2020 | 1276 | 0.12 | Why? |
| Immunization, Secondary | 1 | 2021 | 1649 | 0.12 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.12 | Why? |
| Antibody Diversity | 1 | 2012 | 10 | 0.12 | Why? |
| Interleukin-4 | 1 | 2014 | 367 | 0.12 | Why? |
| Drug Resistance, Viral | 1 | 2018 | 1083 | 0.11 | Why? |
| Cell Line, Tumor | 1 | 2020 | 3608 | 0.11 | Why? |
| Immunoglobulin Class Switching | 1 | 2012 | 133 | 0.11 | Why? |
| Biopsy | 1 | 2021 | 2811 | 0.11 | Why? |
| Cytidine Deaminase | 1 | 2012 | 109 | 0.11 | Why? |
| T-Lymphocytes | 2 | 2020 | 6670 | 0.11 | Why? |
| CHO Cells | 3 | 2018 | 831 | 0.11 | Why? |
| Anti-HIV Agents | 3 | 2018 | 2209 | 0.11 | Why? |
| Cricetulus | 3 | 2018 | 936 | 0.11 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.11 | Why? |
| Cell Transformation, Neoplastic | 1 | 2012 | 191 | 0.11 | Why? |
| Cell Differentiation | 1 | 2016 | 1338 | 0.10 | Why? |
| Polysaccharides | 1 | 2018 | 854 | 0.10 | Why? |
| Publishing | 1 | 2020 | 990 | 0.10 | Why? |
| Coronavirus Infections | 9 | 2021 | 253789 | 0.10 | Why? |
| Pneumonia, Viral | 8 | 2021 | 243684 | 0.10 | Why? |
| HIV | 1 | 2017 | 1116 | 0.10 | Why? |
| Protein Domains | 5 | 2021 | 6563 | 0.10 | Why? |
| Convalescence | 1 | 2020 | 2829 | 0.10 | Why? |
| Mice, Knockout | 1 | 2014 | 1815 | 0.10 | Why? |
| Lymphocyte Count | 1 | 2021 | 4758 | 0.09 | Why? |
| Betacoronavirus | 9 | 2021 | 204454 | 0.09 | Why? |
| Interleukins | 1 | 2014 | 762 | 0.09 | Why? |
| Nanoparticles | 1 | 2021 | 2040 | 0.09 | Why? |
| Mexico | 1 | 2017 | 2787 | 0.09 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.09 | Why? |
| Phylogeny | 4 | 2021 | 13341 | 0.09 | Why? |
| Disease Models, Animal | 4 | 2021 | 10998 | 0.09 | Why? |
| Dendritic Cells | 1 | 2016 | 1330 | 0.09 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.08 | Why? |
| Biosensing Techniques | 1 | 2021 | 2116 | 0.08 | Why? |
| Vero Cells | 2 | 2020 | 14117 | 0.08 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.08 | Why? |
| Virus Replication | 4 | 2021 | 14331 | 0.08 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.08 | Why? |
| Translocation, Genetic | 2 | 2017 | 40 | 0.07 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.07 | Why? |
| Mice, Inbred C57BL | 3 | 2021 | 5542 | 0.07 | Why? |
| Macrophages | 1 | 2016 | 2784 | 0.07 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.07 | Why? |
| Macaca mulatta | 3 | 2021 | 3716 | 0.07 | Why? |
| Monocytes | 1 | 2016 | 2978 | 0.07 | Why? |
| Protein Binding | 4 | 2021 | 11430 | 0.06 | Why? |
| Interferometry | 1 | 2021 | 74 | 0.06 | Why? |
| Chimera | 1 | 2020 | 83 | 0.05 | Why? |
| Cell Line | 3 | 2021 | 12040 | 0.05 | Why? |
| Immune Evasion | 2 | 2021 | 2081 | 0.05 | Why? |
| Vesiculovirus | 1 | 2020 | 153 | 0.05 | Why? |
| Interferon Regulatory Factor-7 | 1 | 2020 | 234 | 0.05 | Why? |
| Mice, Inbred BALB C | 2 | 2021 | 5814 | 0.05 | Why? |
| Dependovirus | 1 | 2021 | 272 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.05 | Why? |
| Virus Internalization | 1 | 2018 | 7921 | 0.05 | Why? |
| Protein Isoforms | 1 | 2020 | 347 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.05 | Why? |
| Brazil | 1 | 2017 | 12582 | 0.05 | Why? |
| Protein Conformation | 2 | 2021 | 4386 | 0.05 | Why? |
| Genes, Reporter | 1 | 2020 | 472 | 0.05 | Why? |
| Genetic Loci | 1 | 2020 | 439 | 0.05 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.05 | Why? |
| Reassortant Viruses | 1 | 2020 | 287 | 0.05 | Why? |
| Receptors, Antigen, B-Cell | 1 | 2021 | 424 | 0.05 | Why? |
| Protein Array Analysis | 1 | 2020 | 387 | 0.04 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2020 | 610 | 0.04 | Why? |
| Vesicular stomatitis Indiana virus | 1 | 2020 | 354 | 0.04 | Why? |
| Binding Sites | 2 | 2021 | 6201 | 0.04 | Why? |
| Sequence Analysis, Protein | 1 | 2018 | 309 | 0.04 | Why? |
| Gene Knock-In Techniques | 1 | 2017 | 124 | 0.04 | Why? |
| Toll-Like Receptor 3 | 1 | 2020 | 391 | 0.04 | Why? |
| V(D)J Recombination | 1 | 2017 | 16 | 0.04 | Why? |
| Molecular Conformation | 1 | 2018 | 374 | 0.04 | Why? |
| Antigens, Ly | 1 | 2016 | 17 | 0.04 | Why? |
| Peptide Library | 1 | 2020 | 564 | 0.04 | Why? |
| Crystallization | 1 | 2018 | 331 | 0.04 | Why? |
| Injections | 1 | 2018 | 237 | 0.04 | Why? |
| Nitric Oxide Synthase Type II | 1 | 2016 | 119 | 0.04 | Why? |
| Genomic Instability | 1 | 2017 | 80 | 0.04 | Why? |
| Selection, Genetic | 1 | 2020 | 691 | 0.04 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2018 | 593 | 0.04 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.04 | Why? |
| Immune Sera | 1 | 2021 | 884 | 0.04 | Why? |
| Mucous Membrane | 1 | 2018 | 305 | 0.04 | Why? |
| Peer Review, Research | 1 | 2020 | 407 | 0.04 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.04 | Why? |
| Mesocricetus | 1 | 2021 | 1847 | 0.04 | Why? |
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 343 | 0.04 | Why? |
| HLA Antigens | 1 | 2021 | 830 | 0.04 | Why? |
| Epitope Mapping | 1 | 2020 | 1240 | 0.04 | Why? |
| Cell Separation | 1 | 2016 | 270 | 0.04 | Why? |
| Body Weight | 1 | 2021 | 1074 | 0.04 | Why? |
| Structure-Activity Relationship | 1 | 2021 | 2219 | 0.03 | Why? |
| Alleles | 1 | 2020 | 1557 | 0.03 | Why? |
| Virulence | 1 | 2021 | 2172 | 0.03 | Why? |
| Probability | 1 | 2018 | 923 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.03 | Why? |
| Glycosylation | 1 | 2018 | 1255 | 0.03 | Why? |
| Radiography | 1 | 2021 | 1576 | 0.03 | Why? |
| United States | 1 | 2020 | 46150 | 0.03 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.03 | Why? |
| Protein Structure, Tertiary | 1 | 2017 | 1565 | 0.03 | Why? |
| Genes, Immunoglobulin | 1 | 2012 | 50 | 0.03 | Why? |
| Interprofessional Relations | 1 | 2020 | 1013 | 0.03 | Why? |
| Editorial Policies | 1 | 2017 | 408 | 0.03 | Why? |
| Base Sequence | 1 | 2020 | 3581 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Sequence Alignment | 1 | 2018 | 2109 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2021 | 2290 | 0.03 | Why? |
| DNA Repair | 1 | 2012 | 114 | 0.03 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.03 | Why? |
| Immunization | 1 | 2021 | 2019 | 0.03 | Why? |
| Asymptomatic Infections | 2 | 2020 | 7218 | 0.03 | Why? |
| Immunoglobulins | 1 | 2017 | 811 | 0.03 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2017 | 760 | 0.03 | Why? |
| Cricetinae | 1 | 2018 | 3344 | 0.03 | Why? |
| Proteome | 1 | 2020 | 1812 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.03 | Why? |
| Software | 1 | 2021 | 2501 | 0.02 | Why? |
| Respiratory System | 1 | 2021 | 3213 | 0.02 | Why? |
| Flow Cytometry | 1 | 2016 | 2393 | 0.02 | Why? |
| Infant | 2 | 2021 | 30274 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2017 | 3395 | 0.02 | Why? |
| Critical Illness | 2 | 2021 | 17281 | 0.02 | Why? |
| Child, Preschool | 2 | 2021 | 36283 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2017 | 3786 | 0.02 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.02 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2020 | 4027 | 0.02 | Why? |
| Transcription, Genetic | 1 | 2012 | 1326 | 0.02 | Why? |
| Antibodies | 1 | 2012 | 846 | 0.02 | Why? |
| Antibody Formation | 1 | 2018 | 4038 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Receptors, Virus | 1 | 2020 | 5659 | 0.02 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.02 | Why? |
| Communication | 1 | 2020 | 5206 | 0.01 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2017 | 5837 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Genome, Viral | 1 | 2021 | 13157 | 0.01 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.01 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.01 | Why? |
| RNA, Viral | 1 | 2017 | 32276 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |